Intramuscular vascular endothelial growth factor gene therapy: Fact or fiction?

American Journal of Medicine

Volumn 114, Issue 2, 2003, Pages 156-157

  Baumgartner, Iris ^a  

^a Kantonsspital Frauenfeld   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 4; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN C; VASCULOTROPIN[121]; VASCULOTROPIN[165];

ANGIOGENESIS; ANGIOMA; DOSE CALCULATION; DRUG ACTIVITY; DRUG EFFECT; GENE THERAPY; GENE TRANSFER; HEART MUSCLE ISCHEMIA; HEART PERFUSION; HUMAN; LIMB ISCHEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY;

EID: 0037315666     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(02)01533-4     Document Type: Editorial

References (13)

1. Nabel E.G., Plautz G., Nabel G.J. Site-specific gene expression in vivo by direct gene transfer into arterial wall. Science. 249:1990;1285-1288.
2. Baumgartner I., Pieczek A., Manor O., et al. Constitutive expression of phVEGF165 following intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 97:1998;1114-1123.
3. Henry T.D., Abraham J.A. Review of preclinical and clinical results of vascular endothelial growth factors for therapeutic angiogenesis. Curr Interv Cardiol Rep. 2:2000;228-241.
4. Comerota A.J., Throm R.C., Miller K.A., et al. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia preliminary results of a phase I trial. J Vasc Surg. 35:2002;930-936.
5. Wolff J.A., Malone R.W., Williams P., et al. Direct gene transfer into mouse muscle in vivo. Science. 247:1990;1465-1468.
6. Shyu K.-G., Chang H., Wang B.-W., Kuan P. Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia. Am J Med. 114:2003;85-92.
7. Isner J.M., Pieczek A., Schainfeld R., et al. Clinical evidence of angiogenesis following arterial gene transfer of phVEGF165 in a patient with ischemic limb. Lancet. 348:1996;370-374.
8. Baumgartner I., Rauh G., Pieczek A., et al. Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor. Ann Intern Med. 132:2000;880-884.
9. Flamme I., von Reutern M., Drexler H.C.A., Syed-Ali S., Risau W. Overexpression of vascular endothelial growth factor in the avian embryo induces hypervascularization and increased vascular permeability without alterations of embryonic pattern formation. Dev Biol. 11:1995;399-414.
10. Springer M.L., Chen A.S., Kraft P.E., Bednarski M., Blau H.M. VEGF gene delivery to muscle potential role for vasculogenesis in adults. Mol Cell. 2:1998;549-558.
11. Dor Y., Djonov V., Abramovitch R., et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J. 21:2002;1939-1947.
12. Kreis R., Bruegger K., Skjelsvik C., et al. Quantitative 1H magnetic resonance spectroscopy of myoglobin de- and re-oxygenation in skeletal muscle reproducibility and effects of location and disease. Magn Reson Med. 46:2001;240-248.
13. Labs K.-H., Dormandy J.A., Jaeger K., Stuerzebecher C.-S., Hiatt W.R. Transatlantic Conference on Clinical Trial Guidelines in Peripheral Arterial Disease clinical trial methodology. Circulation. 100:1999;75-81.